

**Minimally invasive diagnostics and immunotherapy of lung cancer** Talebian Yazdi, M.

## Citation

Talebian Yazdi, M. (2017, April 18). *Minimally invasive diagnostics and immunotherapy of lung cancer*. Retrieved from https://hdl.handle.net/1887/48820

Version:	Not Applicable (or Unknown)
License:	<u>Licence agreement concerning inclusion of doctoral thesis in the</u> <u>Institutional Repository of the University of Leiden</u>
Downloaded from:	https://hdl.handle.net/1887/48820

Note: To cite this publication please use the final published version (if applicable).

Cover Page



# Universiteit Leiden



The handle <u>http://hdl.handle.net/1887/48820</u> holds various files of this Leiden University dissertation

Author: Talebian Yazdi, M. Title: Minimally invasive diagnostics and immunotherapy of lung cancer Issue Date: 2017-04-18

# Chapter 6

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer

M. Talebian Yazdi<sup>1</sup> M.S. Schinkelshoek<sup>1</sup> N.M. Loof<sup>2</sup> C. Taube<sup>1</sup> P.S. Hiemstra<sup>1</sup> M.J.P. Welters<sup>2</sup> S.H. van der Burg<sup>2</sup>

1. Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands

2. Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands

Authorship note: M. Talebian Yazdi and M.S. Schinkelshoek contributed equally to this study and share first authorship.

Oncoimmunology. 2016 Nov 8;5(12):e1255393

#### ABSTRACT

#### Introduction

Advanced non-small cell lung cancer (NSCLC) is traditionally treated with platinumbased chemotherapy and radiotherapy. Since immunotherapy holds promise for treating advanced NSCLC, we assessed the systemic effects of the traditional therapies for NSCLC on immune cell composition and function.

#### Methods

Eighty-four pulmonary adenocarcinoma patients, treated either with chemotherapy or radiotherapy, were studied. A prospective study of 23 patients was conducted in which the myeloid and lymphoid cell compartments of peripheral blood were analyzed. Changes in cell populations were validated in a retrospective cohort of 61 adenocarcinoma patients using automated differential counts collected throughout therapy. Furthermore, the functional capacity of circulating T cells and antigen-presenting cells (APC) was studied. Blood samples of healthy individuals were used as controls.

#### Results

In comparison to healthy controls, untreated adenocarcinoma patients display an elevated frequency of myeloid cells coinciding with relative lower frequencies of lymphocytes and dendritic cells. Standard chemotherapy had no overt effects on myeloid and lymphoid cell composition nor on T-cell and APC-function. In contrast, patients treated with radiotherapy displayed a decrease in lymphoid cells and a relative increase in monocytes/macrophages. Importantly, these changes were associated with a reduced APC function and an impaired response of T cells to recall antigens.

#### Conclusions

Platinum-based standard of care chemotherapy for NSCLC has no profound negative effect on the immune cell composition and function. The negative effect of prolonged low-dose radiotherapy on the immune system warrants future studies on the optimal dose and fraction of radiotherapy when combined with immunotherapy.

#### INTRODUCTION

Conventional therapies for advanced non-small cell lung cancer (NSCLC) consist of platinum-based chemotherapy combined with a third generation cytotoxic drug (stage IV) or concurrent chemoradiotherapy (stage III)<sup>1,2</sup>. The traditional view that these standard of care therapies cause immunosuppression and therefore cannot be combined with new and promising forms of immunotherapy for advanced NSCLC, such as immune checkpoint antibodies targeting the programmed death 1 (PD-1) receptor and its ligand PD-L1<sup>3</sup>, has been challenged in recent years<sup>4-7</sup>. Next to their direct cytotoxic effect, platinum-based compounds can also promote anti-cancer immune responses, for example by enhancing T-cell activation by dendritic cells (DCs) as part of immunogenic cell death. Furthermore, platinum chemotherapy manipulates the tumor microenvironment by sensitizing tumor cells to cytotoxic T cell (CTL)-mediated attack or by upregulation of MHC class I<sup>8,9</sup>. Radiotherapy has various immunomodulatory effects such as promoting DC maturation<sup>10</sup>, local production of type-I interferon<sup>11</sup> as well as upregulation of MHC class I and tumor-specific antigens<sup>12</sup>, all of which support tumor-specific effector T cells. These insights on the immune-potentiating effects of both chemotherapy and radiotherapy have led to the rationale that combining these conventional anti-cancer therapies with new forms of T cell-based immunotherapies can have synergistic effects and, possibly, result in improved clinical outcomes<sup>4-7</sup>.

However, the beneficial effects of chemotherapy and radiotherapy on anti-tumor immunity are mainly documented in animal models and *in vitro* studies. Information on how these therapies affect the human immune system is lacking, in particular in NSCLC patients. To address this, patients with advanced pulmonary adenocarcinoma, the most prevalent subtype of NSCLC<sup>13</sup>, treated with platinum-based chemotherapy or chemoradiotherapy were analyzed for the effect of therapy on myeloid and lymphoid cell composition in the circulation. Furthermore, the functionality of circulating T cells and antigen-presenting cells (APC) was investigated upon standard of care therapy. Our study reveals that, while standard platinum-based chemotherapy does not affect immune cell composition and function, radiotherapy has a negative effect on the number and function of circulating T cells and APCs.

#### MATERIALS AND METHODS

#### Patients and tissue collection

Between March 2011 and April 2014, a prospective study was conducted in patients with histologically proven pulmonary adenocarcinoma, who were treated at the outpatient clinic of the Department of Pulmonology from three hospitals (Leiden University Medical

Center, Alrijne Ziekenhuis and Groene Hart Ziekenhuis). Patients were grouped according to their received therapy. Patients in the first group (carboplatin-vinorelbine) were treated with a 21-day chemotherapy cycle in which they were administered carboplatin (AUC 5 regimen, depending on renal function) and vinorelbine (25 mg/m<sup>2</sup>) on day 1, as well as vinorelbine (25 mg/m<sup>2</sup>) monotherapy on day 8. The second group (carboplatinpemetrexed) was composed of patients treated with carboplatin (AUC 5 regimen) and pemetrexed (500mg/m<sup>2</sup>) on day 1. In both groups, at least three cycles of chemotherapy were administered every 3 weeks. Patients in the last group (radiotherapy) received a 5-week cycle of concurrent chemoradiotherapy in which a daily radiation dose of 2.75 Gy (delivered in 24 fractions) was preceded by low-dose cisplatin (6 mg/m<sup>2</sup>) as a radiosensitizer. From all patients, venous blood samples were collected prior to treatment with chemotherapy or radiotherapy (baseline) and at least 14 days after cessation of therapy (post therapy). From all blood samples, pperipheral blood mononuclear cells (PBMC) were isolated by Ficoll-density centrifugation according to standard operating procedures (SOP) <sup>14</sup> and used for analysis of recall antigen T cell response, mixed lymphocyte reaction (MLR) and flow-cytometric phenotyping.

A retrospective cohort of pulmonary adenocarcinoma patients, treated between 2008 and 2014 with at least three chemotherapy cycles of 21 days (carboplatin-vinorelbine and carboplatin-pemetrexed), was analyzed by collecting automated differential counts from blood samples before start of therapy (baseline), at two time points during the 21-day chemotherapy cycle at week 2 and week 3, and at least 14 days after cessation of therapy (post therapy). From patients treated with a 5-week cycle of radiotherapy, we retrieved automated differential counts at baseline, after each week during the 5-week cycle and at least 14 days after radiotherapy was completed (post therapy). Based on the analysis of this historical cohort, we included an additional five adenocarcinoma patients from whom blood samples were taken at baseline, at week 2 and week 3 of the 21-day chemotherapy cycle, for phenotyping and functional analyses.

#### Analysis of recall antigen T cell response

The capacity of T cells to proliferate upon stimulation with recall antigens was assessed in a 3-day proliferation assay with memory response mix (MRM), composed of tetanus toxoid (Netherlands Vaccine Institute), tuberculin purified protein derivative (Netherlands Vaccine Institute), and Candida (HAL Allergenen Lab), as previously published by our research group <sup>15</sup>. Briefly, cryopreserved PBMCs were thawed and in triplicate wells (1.0 x 10<sup>5</sup> cells/well) exposed to three conditions: medium control (90% IMDM supplemented with 10% human AB serum (PAA laboratories, Pasching, Austria)), MRM and Phytohaemagglutinin (PHA, 0.5  $\mu$ g/mL), which was used as a positive control. Proliferation was measured by <sup>3</sup>H-thymidine incorporation during the last 18 hours of the assay. A positive response was defined as equal or above a stimulation index (SI) of 3. This SI was calculated by dividing the mean counts of stimulated wells by that of the medium control wells.

#### Mixed lymphocyte reaction (MLR)

To assess the antigen presenting capacity of patient PBMCs, a mixed lymphocyte reaction (MLR) was performed according to  $SOP^{15}$ . Thawed patient PBMCs were irradiated at 3000 rad to prevent proliferation of cells. Next,  $1 \times 10^5$  patient cells/well were seeded in medium in four replicate wells and co-cultured for 7 days with HLA-mismatched third party non-irradiated lymphocytes ( $1 \times 10^5$  cells/well) isolated from buffy coats obtained from healthy donors. Proliferation was measured by <sup>3</sup>H-thymidine incorporation during the last 18 hours of the assay. As negative controls, irradiated patient PBMCs alone and third party non-irradiated PBMCs alone were used. A positive response was defined as a SI index of at least 3, which was calculated as the mean counts in wells containing irradiated patient PBMCs co-cultured with third party lymphocytes divided by the mean counts of unstimulated third party lymphocytes.

#### Flow cytometric phenotyping of PBMCs

Flow cytometry was used to assess the composition of patient PBMCs before, during and after treatment. PBMCs of eight healthy donors were analyzed for comparison. PBMCs were thawed, washed and stained according to SOPs<sup>14,16</sup> for the T-cell markers by using antibodies against CD3 (Pacific Blue; DAKO, Glostrup, Denmark), CD4 (PE-CF594; BD Biosciences, San Jose, CA, USA) CD8 (APC-Cy7; BD) and inhibitory T cell markers PD-1 (BV-605, BioLegend, San Diego, CA, USA), NKG2A (AF700, BD), TIM3 (PE, BioLegend) and CTLA-4 (PE-Cy7; BD). Furthermore, in parallel PBMCs were stained with a set of monocyte/macrophage and dendritic cell (DC) markers. This set was comprised of antibodies against CD1a (FITC; BD), CD3 (Pacific Blue; DAKO), CD11b (PE, BD), CD11c (Alexa Fluor 700; BD), CD14 (PE-Cy7; BD), CD16 (PE-CF594; BD), CD19 (Brilliant Violet 605; BD), CD45 (PerCP-Cy5.5; BD), CD163 (APC; R&D Systems, Minneapolis, MN, USA), CD206 (APC-Cy7; BioLegend) and HLA-DR V500 (BD;). Finally, in a separate experiment PBMCs were stained for regulatory T cell (Treg) markers CD3 (V500, BD), CD4 (AF700, BD), CD25 (PE-Cy7, BD), CD127 (BV650, BD), Foxp3 (PE-CF594, BD), Ki67 (FITC, eBiosciences), Helios (APC, Biolegend) and CD45RA (APC-H7, BD). For each sample 1,000,000 events were acquired by flow cytometry (BD LSR Fortessa). Data analysis was performed with BD FACSDiva software (version 6.2) using a gating strategy that was recently published by our research group<sup>15,16</sup>. This strategy is shown in **Supplementary Figure 1**.

Tregs were classified into three subtypes according to a recent paper by Santegoets et al.<sup>17</sup>: Def 1: CD4+ CD25+ CD127low Foxp3+; Def 1 (activated Tregs): CD4+ CD25+ CD127low Foxp3+Ki67+; Def 2: CD4+ CD25+ CD127low Foxp3+ Helios+; Def 3a: Fox-p3high CD45RA- (activated Treg) ; Def 3b: Foxp3int CD45RA+ (naïve Treg). Myeloid and

lymphoid cells were defined using the myeloid and lymphoid cell gate within the CD45+ gate. Monocytes/macrophages were defined as CD45+ HLA-DR+ CD1a- CD14+ CD11b+, with subsets of M1 (CD206-CD163-), M2a (CD206+CD163-) and M2c (CD206-CD163+) monocytes/macrophages. DCs were defined as CD45+ HLA-DR+ CD1a- CD11b-CD14- CD11c+CD206-CD163. Myeloid derived suppressor cells (MDSCs) were characterized in the myeloid cell population according to recent literature describing ten separate MDSC subtypes<sup>18</sup>.

#### Statistical analysis

The Mann-Whitney U test, a non-parametric test for independent samples, was used for statistical comparison of untreated pulmonary adenocarcinoma patients and healthy control PBMCs with regards to lymphoid and myeloid cell populations. For the patients who underwent chemotherapy or radiotherapy, the Wilcoxon signed-rank test (non-parametric test for paired samples) was used to compare recall antigen T-cell response and MLR at baseline and post therapy. This test was also used for analysis of T cell, monocyte/macrophage and DC markers throughout therapy. Percentages within the CD45+ gate (monocytes/macrophage and DC markers) or the lymphoid gate (T cell markers) were used in non-parametric testing. A p-value < 0.05 was considered statistically significant. Statistical software package SPSS 20.0 (SPSS, Chicago, IL, USA) was used for data analysis.

#### Ethical approval

The study protocol was submitted to and approved by the Medical Ethical Committee of the Leiden University Medical Center (P10.187). All patients gave written informed consent prior to participation.

#### RESULTS

Twenty-three pulmonary adenocarcinoma patients (14 males, 9 females) with a median age of 61 years (range 48-79 years) were prospectively analyzed. Ten patients were treated with carboplatin-vinorelbine, seven patients received carboplatin-pemetrexed treatment and six patients underwent radiotherapy. The group of 8 healthy controls, who supplied donor PBMCs consisted of 7 females and 1 male with a median age of 55 years (range 38-67 years). A summary of patient characteristics is displayed in **Table 1**.

Number of patients with pulmonary adenocarcinoma	n=23	
Age, median (range)	61 years (48-79 years)	
Gender, Male/Female	14/9	
Stage		
1/11	n=2	
III	n=11	
IV	n=10	
Treatment		
Carboplatin-vinorelbine	n=10	
Carboplatin-pemetrexed	n=7	
Radiotherapy	n=6	

Table 1. Summary of patient characteristics

### Pulmonary adenocarcinoma patients display cancer-driven changes in lymphoid and myeloid cell frequency

First, baseline differences in circulating myeloid and lymphoid cell populations between untreated pulmonary adenocarcinoma patients and healthy controls were analyzed (Figure 1). Patients showed a significantly elevated level of myeloid cells coinciding with a lower frequency of circulating lymphoid cells (Figure 1A) independent of their gender. Although no difference was observed between patients and healthy controls with respect to CD4+ and CD8+ T cell frequency gated as percentage of the lymphoid gate (Figure 1B), a lower frequency of CD4+ T cells was noted in adenocarcinoma patients when gated as percentage of the CD45+ gate, and a similar trend was seen for CD8+ T cells, fitting with the observation that the percentage of lymphoid cells is decreased while the percentage of myeloid cells is increased (Supplementary Figure 2). Subset analysis of the myeloid cell populations, demonstrated a higher percentage of CD11b+/ CD14+ monocytes/macrophages (Figure 1C) and a lower percentage of CD11b-CD14-CD11c+CD206-CD163- dendritic cells (DCs) (Figure 1D) in the PBMC of the patients when compared to that of healthy donors. No difference was observed with respect to MDSC frequency and expression of inhibitory T cell markers between adenocarcinoma patients and healthy donors (Supplementary Figure 3). Thus, adenocarcinoma patients show a tumor-associated abnormal level of myeloid cells which is mainly caused by increased numbers of monocytes/macrophages while in parallel the frequency of circulating lymphoid cells and dendritic cells is lower.

# Changes in immune cell composition after standard of care treatment for NSCLC

Next, the effect of standard of care NSCLC treatment modalities on immune cell composition was assessed. In the patient group treated with carboplatin-vinorelbine (n=5),



Figure 1. Baseline differences in lymphoid and myeloid cells in healthy controls and pulmonary adenocarcinoma patients

Flow-cytometric phenotyping of peripheral blood mononuclear cells (PBMCs) of 23 untreated pulmonary adenocarcinoma patients and 8 healthy donors was performed to analyze myeloid cells, lymphoid cells, CD4+ and CD8+ T cells, monocytes/macrophages (CD45+HLA-DR+ CD1a-CD11b+/CD14+) and dendritic cells (CD11b-/CD14- CD11c+/CD206-/CD163-) using a gating strategy presented in **Supplementary Figure 1**. Shown are lymphoid and myeloid cells (**A**), CD4+ and CD8+ T cells as percentage of the lymphoid gate (**B**), monocytes/macrophages (**C**) and dendritic cells (**D**) as percentages of the CD45+ gate. Data is shown as mean with standard deviation (SD) and Mann-Whitney U test was used for statistical analysis (\*\* p < 0.01, \* p < 0.05, NS = non-significant).

treatment did not result in overt changes in the percentage of lymphoid and myeloid cells. However, subset analysis of the myeloid cell population showed that carboplatinvinorelbine treatment caused an increase in DCs and a decrease in monocytes/macrophages (**Figure 2A**). Treatment with carboplatin-pemetrexed (n=7) similarly had no profound effect on the composition of the myeloid and lymphoid cell compartments. Here, a treatment-related increase was observed for both the percentage of monocytes/ macrophages and the percentage of DCs (**Figure 2B**). The treatment of patients with radiotherapy (n=6) resulted in a slight decrease in the percentage of lymphoid cells and a concomitant increase in myeloid cells, which was not likely to be associated with more extensive irradiation as there is no relation between the irradiated tumor volume and extent of lymphopenia in this small group of patients (**Supplementary Figure 4**). The lower frequency of lymphocytes as compared with healthy donors remained after cessation of radiotherapy. An increase of the percentage of monocytes/macrophages was observed (**Figure 2C**). All three treatment groups did not display changes in the frequency of T cells expressing inhibitory markers (**Supplementary Figure 3**) or Tregs (**Supplementary Figure 5**). Patients treated with radiotherapy displayed a significant increase in the frequency of MDSC type 4 (CD14+ HLA-DR<sup>Iow</sup>) and MDSC type 7 (CD14+ CD33+ HLA-DR<sup>Iow</sup>) cells (**Supplementary Figure 3**).

# Standard of care NSCLC therapies cause transient and permanent changes in absolute lymphocyte and monocyte counts during therapy

To validate these observations and to obtain more detailed insight into the changes in immune cell composition during treatment, we analyzed the lymphocyte and monocyte counts in a historical cohort of pulmonary adenocarcinoma patients for whom automated leucocyte differential counts were retrieved (Figure 3). In 22 patients, who were treated with carboplatin-vinorelbine (Figure 3A), a small drop in absolute lymphocyte cell counts from baseline (mean 1.87 x 10<sup>9</sup> cells) was observed in week 2 of the first cycle (cycle 1.1, mean 1.41 x  $10^9$  cells, p<0.05), which normalized at week 3 within the same cycle (cycle 1.2, mean 1.63 x 10<sup>9</sup> cells, p<0.01). Lymphocyte counts remained stable during therapy, and there was no effect on absolute lymphocytes counts post therapy when compared to baseline (mean  $1.61 \times 10^{9}$  cells, p=0.98). On the other hand, carboplatin-vinorelbine treatment caused a strong decline in absolute monocyte counts from baseline (mean  $0.81 \times 10^{\circ}9$  cells), which is evident in week 2 of the first cycle (cycle 1.1, mean 0.22 x  $10^{9}$  cells, p<0.001), but almost recovers a week later during the same 21-day cycle (cycle 1.2, mean 0.57 x 10<sup>9</sup> cells, p<0.001), only to drop again sharply in the next chemotherapy cycle (cycle 2.1, mean 0.09 x  $10^{9}$  cells, p<0.05). After therapy cessation, absolute monocyte cell counts show a quick recovery nearly to the baseline level (mean  $0.75 \times 10^{6}$  cells, p<0.05), explaining the results of our prospective patient group (Figure 2A). The analysis of 16 patients treated with carboplatin-pemetrexed showed no changes in absolute numbers of lymphocytes and monocytes during or after the course of chemotherapy (Supplementary Figure 6).

Finally, 23 adenocarcinoma patients treated with radiotherapy were analyzed (**Figure 3B**). The baseline absolute lymphocyte numbers (mean 1.88 x 10<sup>9</sup> cells) showed a significant decline during the course of radiotherapy, which persisted in the last week of the 5-week treatment cycle (Cycle 5, mean 0.49 x 10<sup>9</sup> cells, p<0.001) and despite a recovery after completion of treatment, the total lymphocyte counts remained lower than baseline (post therapy, mean 0.96 x 10<sup>9</sup> cells, p<0.01). Baseline monocyte counts (mean 0.68 x 10<sup>9</sup> cells) generally remained stable during radiotherapy treatment, with only a small drop observed after week 5 (Cycle 5, mean 0.44 x 10<sup>9</sup> cells, p<0.05). This modest effect disappeared after treatment (post therapy, mean 0.67 x 10<sup>9</sup> cells, p=0.90). The absolute loss in lymphocytes and stable number of monocytes explains the treatment-





Peripheral blood of 18 pulmonary adenocarcinoma patients was analyzed for lymphoid and myeloid cell composition (depicted as percentages of the CD45+ gate) as well as changes in monocyte/macrophage (CD14+ CD11b+) and dendritic cell (CD11b-CD14-CD11c+CD206-CD163-) frequency. This was done prior to treatment (baseline) and at least 14 days after cessation of therapy (post therapy). Three treatment groups were assessed: carboplatin-vinorelbine (**A**, n=5), carboplatin-pemetrexed (**B**, n=7) and radiotherapy (**C**, n=6). Healthy donor PBMC were taken along for comparison. The fold change of post therapy from baseline is given for the patients concerning the monocyte/macrophage and dendritic cell frequencies. Data is shown as mean with SD and Mann-Whitney U test (healthy controls compared to patients at baseline) and Wilcoxon signed rank test (patients at baseline compared to post therapy) were used for statistical analysis (\*\*\* p<0.001, \*\* p< 0.05, NS non-significant).

related relative drop in the lymphocyte to monocyte ratio observed in our prospective patient group (**Figure 2C**).

# Radiotherapy impairs recall T-cell responses and APC function in patients with pulmonary adenocarcinoma

Subsequently, we tested the impact of these therapies on the stimulatory capacity of APCs and on the responsiveness of T cells to antigenic stimulation (Figure 4). The APCs isolated from patients, who were treated with either carboplatin-vinorelbine or carboplatin-pemetrexed, displayed a good capacity to stimulate allogeneic lymphocytes both at baseline and after chemotherapy in a mixed lymphocyte reaction (MLR) assay. Moreover, none of the chemotherapy schedules influenced the T-cell response to a mix of recall antigens (MRM). In addition, T-cell reactivity to mitogenic stimulation with PHA was strong at baseline and not affected by chemotherapy (Figure 4A and 4B). Based on the marked decrease in absolute monocyte counts within the 21-day carboplatin-vinorelbine treatment (Figure 3A), we prospectively collected PBMCs from five additional patients at three time points (baseline, week 2 and week 3) during the course of their chemotherapy cycle (Supplementary Figure 7). In these five patients, the absolute decrease in monocytes observed in their leucocyte differential counts (Supplementary Figure 7A) was reflected by a relative decrease in myeloid cells (p<0.05) and a concomitant increase in lymphoid cells (p=0.06) (Supplementary Figure 7C). The sharp decline in myeloid cells was mirrored by a drop in monocytes/macrophages. Analysis of M1/M2a/M2c monocytes/macrophages showed a similar decline in all subsets (Supplementary Figure 7C). The observed changes in myeloid cells did not lead to overt changes in the response of T cells to recall antigens or that of APC to stimulate allogeneic T cell reactivity (Supplementary Figure 7B).

In contrast, the T cells of patients, who were treated with radiotherapy, demonstrated a significant decline in their reactivity to recall antigens (**Figure 4C**, mean baseline MRM response SI index 4.4, post therapy mean MRM response 1.5, p<0.05). This decline in T cell reactivity coincided with a weaker MLR response post radiotherapy (mean SI index 7.9) compared to baseline (mean SI index 16.0, p<0.05). Since the PHA-stimulated T cells showed a good proliferative response before (mean SI index 106.4) and after radiotherapy (mean SI index 128.2), reflecting an intact intrinsic capacity of T cells to proliferate, our data suggest that the negative effect of radiotherapy upon the proliferative capacity of PBMCs to stimulation with recall antigens might be related to a hampered APC function.

Taken together, standard of care chemotherapy schedules for pulmonary adenocarcinoma have no profound effect on both the levels and function of myeloid and lymphoid cells in the peripheral blood. The negative effect of radiotherapy on the recall T-cell response can not be explained by the absolute decrease in lymphoid cells only but is also Α

## Carboplatin-vinorelbine





From 22 pulmonary adenocarcinoma patients treated with at least three cycles of carboplatin-vinorelbine (**A**), automated leucocyte differential counts were retrospectively collected at two time points (at week 2 and week 3) during a 21-day cycle of chemotherapy. Weekly automated leucocyte differential counts were also collected from 23 patients treated with a 5-week cycle of radiotherapy (**B**). From all patients, counts were retrieved at baseline and post therapy. Results are presented as mean lymphocyte and monocyte counts (per 10<sup>9</sup> cells) with SD. Wilcoxon signed rank test was used for statistical analysis (\*\*\* p<0.001, \*\* p< 0.01, \* p< 0.05, NS non-significant)

related to the impaired APC function which might be fostered by the relative increase in monocytes/macrophages.



**Figure 4.** Effect of standard of care pulmonary adenocarcinoma therapies on T cell and APC function PBMCs of 18 patients with pulmonary adenocarcinoma were tested for the capacity of T cells to proliferate upon stimulation with phytohaemagglutinin (PHA) or with recall antigens (memory response mix, MRM). Antigen-presenting cell (APC) function was tested by mixed leucocyte reaction (MLR). Three treatment groups were investigated: carboplatin-vinorelbine (**A**, n=5), carboplatin-pemetrexed (**B**, n=7) and radio-therapy (**C**, n=6). Data is shown as mean stimulation index (SI) at baseline and at least 14 days after cessation of therapy (post therapy). Wilcoxon signed rank test was used for statistical analysis (\*\*\* p<0.001, \*\* p< 0.01, \* p< 0.05, NS non-significant)

#### DISCUSSION

In the present study, we demonstrate that treatment of advanced pulmonary adenocarcinoma patients with radiotherapy has several negative effects on circulating immune cells. The most striking observation is a persistent drop in lymphocyte counts during treatment, which coincides with a decline in reactivity of T cells to recall antigens after completion of radiotherapy. Previously, lymphocytopenia has been observed as a side-effect of radiotherapy <sup>19,20</sup> and a negative association of lymphocytopenia with OS has been reported, both for NSCLC and other cancer types<sup>21,22</sup>. Spearman correlation analysis failed to show a relation between the tumor volume irradiated and the observed lymphocytopenia (Supplementary Figure 4), however this might be due to a small sample size (n=6). The fact that radiotherapy aimed at smaller target volumes can reduce lymphocytopenia in cancer patients is well known and discussed in more detail elsewhere<sup>23</sup>.

Whether radiotherapy also affects lymphocyte function has been less well described in cancer patients. Radiotherapy has been shown to negatively affect T-cell responses to recall antigens in testis carcinoma patients who received adjuvant localized radiotherapy<sup>24</sup> and in patients with Hodgkin's disease treated with mantle field irradiation<sup>25</sup>. This study is the first to report a negative functional effect of radiotherapy with respect to circulating T cells in pulmonary adenocarcinoma patients. This effect is unlikely to be caused by infusion with low-dose cisplatin (6 mg/m<sup>2</sup>) that preceded radiotherapy fractions, since cisplatin has been shown to stimulate anti-tumor immunity, in particular by the induction of tumor-specific CD8+ T cells, by promoting infiltration of inflammatory APCs harbouring T-cell costimulatory ligands into the tumor, and by improving cure rates when combined with long peptide vaccines<sup>26,27</sup>. The detrimental effect on APC function by radiotherapy before and after therapy (**Figure 4**) could in part explain this decline in recall-directed T-cell function. Studies on the association of radiotherapy with antigen-presenting capacity of PBMC in NSCLC patients are scarce. Only one study has reported a decline in MLR response and a concomitant decline in PHA-stimulated T-cell proliferation in NSCLC patients who underwent radiotherapy<sup>28</sup>. Our finding that radiotherapy hampers APC stimulatory capacity, potentially explained by decreased APC function or by the suppressive effect of MDSC subtypes which are present at higher frequencies after radiation, contradicts data from mouse studies reporting a beneficial role of radiotherapy with respect to DC maturation and activation<sup>4,6</sup>. For example, one study in C57BL/6 mice bearing B16gp melanoma tumors demonstrated that local irradiation with a single high dose of 10 Gy resulted in upregulation of CD70 and CD86 on local DCs, both of which are costimulatory molecules involved in T-cell priming<sup>10</sup>. In contrast, NSCLC patients in our study received a daily dose of 2.75 Gy with a total of 24 fractions, amounting to a total dose of 66 Gy during the course of 5 weeks. One possible explanation for the discrepancy between our results and findings from mouse studies is that a single high dose or a few fractions of high-dose radiotherapy are needed to recruit circulating immune cells to the tumor site, whereas continuous low dose irradiation over the course of five weeks may finally kill these tumor-infiltrating cells before they can even exert their tumoricidal function. In this light, future studies should address how the immune system is influenced by stereotactic ablative body radiotherapy, a form of high precision radiotherapy with high radiation doses in a few fractions which has achieved excellent tumor control rates in early stage NSCLC<sup>29</sup>. Regardless, our results indicate that prolonged low-dose radiotherapy negatively affects T-cell and APC function in pulmonary adenocarcinoma patients, a matter which needs to be addressed when considering combinatorial approaches with T cell based immunotherapies.

Another important observation from this study is the strikingly high frequency of myeloid cells in the peripheral blood of pulmonary adenocarcinoma compared to healthy subjects (Figure 1). Elevated levels of circulating myeloid-derived suppressor cells (MDSC) have been previously reported in advanced NSCLC and their presence was negatively associated with the frequency of CD8+ T lymphocytes<sup>30,31</sup>, which is in line with our observation of decreased lymphoid cells in the PBMC of advanced pulmonary adenocarcinoma patients compared to healthy donors. Recently, our research group demonstrated that abnormal levels of circulating myeloid cells in cervical carcinoma patients were shown to normalize after treatment with carboplatin and paclitaxel. Importantly, this was associated with higher T-cell reactivity against common microbial recall antigens<sup>15</sup>. In the present study, advanced pulmonary adenocarcinoma patients, who were treated with carboplatin and vinorelbine also demonstrated a sharp decline in circulating myeloid cell populations (Figure 3), but this did not result in changes in recall antigen response to MRM or changes in ability of APCs to stimulate allogeneic T-cell proliferation (MLR response) (**Supplementary Figure 7**). Several factors might explain this apparent discrepancy between our pulmonary adenocarcinoma patients and the cervical cancer patients, such as the use of a different third generation cytotoxic drug in this study cohort. Another important contributing factor might be the impaired APC function of the adenocarcinoma patients at baseline. This is not only reflected by the relative low frequency of DCs in the treatment-naïve patients (Figure 1), but moreover by the relatively weak MLR response at baseline (Figure 4, mean MLR SI index of 11.5) when compared to cervical cancer patients (mean MLR SI index of >50)<sup>15</sup>. This difference in APC function of advanced NSCLC patients might be related to smoking, which is the main risk factor for development of NSCLC<sup>13</sup>. In vitro studies have shown that nicotine diminishes DC activation and maturation thereby promoting T-cell polarization to the T-helper 2 phenotype<sup>32,33</sup>. Nevertheless, the effect of carboplatin-vinorelbine therapy on reducing levels of immunosuppressive myeloid cell populations in pulmonary adenocarcinoma patients is remarkable and further studies into its effect on anti-tumor T-cell immunity are warranted.

In conclusion, this study shows that standard platinum-based chemotherapy used in advanced pulmonary adenocarcinoma patients has no profound adverse effects with respect to immune cell composition and function. Hence, no theoretical objection exists to combining these chemotherapy schedules with novel T-cell based immunotherapies. However, the decline in function of circulating T cells and APCs caused by prolonged low-dose radiotherapy impairs systemic immunity in these patients, which warrants further debate and studies on how radiation can be optimally applied (e.g. by hypofractionated treatment targeting smaller volumes) in order to sustain anti-tumor immunity and perhaps to act synergistically when combined with new forms of T-cell based immunotherapy in NSCLC patients.

#### **REFERENCE LIST**

- 1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013;382:709-19.
- de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. CochraneDatabaseSystRev 2013;8:CD009256.
- Viteri S, Gonzalez-Cao M, Barron F, Riso A, Rosell R. Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. TranslLung Cancer Res 2015;4:756-62.
- Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer immunology, immunotherapy : CII 2015.
- Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. NatRevDrug Discov 2012;11:215-33.
- 6. Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, van den Broek M. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology 2012;1:1610-1.
- 7. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature reviews Cancer 2016.
- 8. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research 2014;20:2831-7.
- 9. Okita R, Yukawa T, Nojima Y, et al. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Cancer immunology, immunotherapy : CII 2016;65:499-509.
- 10. Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. Journal of immunology (Baltimore, Md : 1950) 2012;189:558-66.
- 11. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer research 2011;71:2488-96.
- 12. Sharma A, Bode B, Wenger RH, et al. gamma-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PloS one 2011;6:e28217.
- 13. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. JClinOncol 2005;23:3175-85.
- 14. TalebianYazdi M, Loof NM, Franken KL, et al. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. Cancer ImmunolImmunother 2015;64:1109-21.
- 15. Welters MJ, van der Sluis TC, van Meir H, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Science translational medicine 2016;8:334ra52.
- 16. Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 2015;6:32228-43.
- 17. Santegoets SJ, Dijkgraaf EM, Battaglia A, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer immunology, immunotherapy : Cll 2015;64:1271-86.

- Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloidderived suppressor cells by flow cytometry: results from an interim study. Cancer immunology, immunotherapy : Cll 2016;65:161-9.
- 19. Vuckovic-Dekic L, Susnjar S, Stanojevic-Bakic N, Radosavljevic D. Radio- and chemotherapy variably affect the general immunocompetence of lung cancer patients. Panminerva medica 1999;41:129-33.
- Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14:1071-6.
- 21. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer investigation 2013;31:183-8.
- 22. Grossman SA, Ellsworth S, Campian J, et al. Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2015;13:1225-31.
- 23. Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS oncology 2012;1:149-54.
- 24. Belka C, Ottinger H, Kreuzfelder E, et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;50:199-204.
- 25. van Rijswijk RE, Sybesma JP, Kater L. A prospective study of the changes in immune status following radiotherapy for Hodgkin's disease. Cancer 1984;53:62-9.
- 26. van der Sluis TC, van Duikeren S, Huppelschoten S, et al. Vaccine-induced tumor necrosis factorproducing T cells synergize with cisplatin to promote tumor cell death. Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21:781-94.
- 27. Beyranvand Nejad E, van der Sluis TC, van Duikeren S, et al. Tumor eradication by cisplatin is sustained by CD80/86-mediated costimulation of CD8+ T cells. Cancer research 2016.
- Schulof RS, Chorba TL, Cleary PA, Palaszynski SR, Alabaster O, Goldstein AL. T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha-1. Cancer 1985;55:974-83.
- 29. van Baardwijk A, Tome WA, van Elmpt W, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;105:145-9.
- 30. Wang S, Fu Y, Ma K, et al. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2014;16:616-22.
- Liu CY, Wang YM, Wang CL, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. Journal of cancer research and clinical oncology 2010;136:35-45.
- Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. Journal of immunology (Baltimore, Md : 1950) 2005;175:2684-91.
- 33. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003;109:365-73.





the expression of CD3 and CD19. T cells (CD3+CD19-) were subdivided in CD4+ and CD8+ T cells. Monocytes/macrophages (CD3-CD19- cells) were gated for HLA-DR+ / CD1a- cells and then plotted for CD14 and CD11b. Based on differential expression of CD163, CD166, CD206 and CD11c, monocytes/macrophages were subdivided into Singlets were gated based on FCS-A and FCS-H to exclude dead cells. Then, leucocytes were selected based on high expression of CD45. The CD45+ cells were divided into myeloid cells and lymphoid cells with use of the myeloid cell gate and lymphoid cell gate within the forward-side scatter plots. Also, CD45+ cells were plotted for M1/M2a/M2c and DC subsets.



**Supplementary Figure 2.** Flow-cytometric phenotyping of peripheral blood mononuclear cells (PBMCs) of 23 untreated pulmonary adenocarcinoma patients and 8 healthy donors revealed that CD4+ T cells, displayed as percentage of the CD45+ gate, were significantly lower in patients than in healthy controls (p<0.05) whereas the same trend was observed for CD8+ T cells (albeit not significant). Data is shown as mean with SD and statistical analysis was performed using the Mann-Whitney U test (\* p< 0.05, NS = non-significant).



**Supplementary Figure 3.** Effect of standard of care NSCLC treatment on inhibitory T cell markers and myeloid derived suppressor cells (MDSC).

145

PBMCs of pulmonary adenocarcinoma patients were used for analysis of inhibitory T cell markers (PD-1, NKG2A, TIM3 and CTLA-4 on CD4+/CD8+ T cells) and MDSCs at baseline (pre treatment) and at least 14 days after cessation of therapy (post treatment). Healthy donor PBMCs were taken along for comparison. Three treatment groups were assessed: carboplatin-pemetrexed (n=7), carboplatin-vinorelbine (n=5) and radiotherapy (n=6). All three treatments did not induce changes in T cell inhibitory markers (**B-D**, p> 0.05). Comparison of healthy controls and patients at baseline also did not show a difference in these markers (**A**, p>0.05). Treatment with doublet chemotherapy (carboplatin-pemetrexed and carboplatin-vinorelbine) was not associated with changes in MDSCs (**F-G**, p> 0.05), whereas a significant increase in MDSC type 4 (CD14+ HLA-DRIow) and MDSC type 7 (CD14+ CD33+ HLA-DRIow) was observed in patients treated with radiotherapy (**H**, p<0.05). Trequency of MDSCs was comparable between healthy controls and patients at baseline (**E**, p>0.05). Data is shown as mean with SD and Wilcoxon signed rank test (patients at baseline compared to post therapy) and Mann-Whitney U test (healthy controls compared to patients at baseline) were used for statistical analysis.







SD and Wilcoxon signed rank test was used for statistical analysis.





## Carboplatin-pemetrexed

**Supplementary Figure 6.** Carboplatin-pemetrexed treatment does not alter absolute lymphocyte and monocytes counts during therapy.

Automated differential leucocyte counts were retrieved from a historical cohort of 16 pulmonary adenocarcinoma patients treated with at least three cycles of carboplatin-pemetrexed. Automated leucocyte differential counts were collected at baseline, post therapy and at two time points (at week 2 and week 3) during the 21-day cycle of chemotherapy. Results are shown as mean lymphocyte and monocyte counts (per  $10^9$ cells) with SD. Wilcoxon signed rank test was used for statistical analysis (NS = non-significant).



**Supplementary Figure 7.** Lymphoid and myeloid cells change during carboplatin-vinorelbine treatment without an effect on T-cell and APC function

At three time points (baseline, at week 2 and week 3) during a 21-day cycle of carboplatin-vinorelbine, PBMCs of 5 patients were prospectively collected for flow-cytometric phenotyping, testing of recall antigen

response (MRM) and ability of APCs to stimulate allogeneic T cell proliferation (MLR). Shown are leucocyte differential counts (per 10<sup>6</sup>9 cells) (**A**), Stimulation index (SI) of MRM and MLR response (**B**), and frequency of lymphoid and myeloid cells, monocytes/macrophages and dendritic cells as percentages of the CD45+ gate. Subset analysis is shown for M1 (CD206-CD163-), M2a (CD206+CD163-) and M2c (CD206-CD163+) monocytes/macrophages (**C**). Results are presented as mean with SD and Wilcoxon signed rank test was used for statistical analysis. (\* p< 0.05, NS = non-significant)